WASHINGTON (AP) — FDA scientists are questioning whether study results are reliable enough to warrant approval for a new cancer drug from Johnson & Johnson. J&J’s Ortho Biotech unit has asked the FDA to approve the injectable drug Yondelis for women with recurring ovarian cancer. It would be used with J&J’s cancer drug Doxil. But regulators are concerned the company’s results may not be reliable because of a large number of inconsistencies. The company’s data use imaging scans designed to show a halt in progression of the cancer. But radiology experts hired by J&J disagreed on what the images showed 39 percent of the time. The FDA’s outside cancer experts will weigh in on the results Wednesday.
Related Articles Read More >

Navigating the new regulatory terrain pharma companies face with IRA and 340B

FDA warns against compounded oral ketamine for psychiatric disorders

FDA resolves drug shortage for Novartis’ prostate cancer drug Pluvicto
